Evaluation of several botulinum toxins-A delivering systems into the bladder in interstitial cystitis/painful bladder syndrome (IC/PBS)

Farbod Torkamand; Seyed Javad Mirjavadi; Fatemeh Khatami; Fateme Guitynavard; Seyed Mohammad Kazem Aghamir

Evaluation of several botulinum toxins-A delivering systems into the bladder in interstitial cystitis/painful bladder syndrome (IC/PBS)

Am J Clin Exp Urol. 2019 Oct 25;7(5):346-351. eCollection 2019.

Authors

Farbod Torkamand¹, Seyed Javad Mirjavadi¹, Fatemeh Khatami², Fateme Guitynavard², Seyed Mohammad Kazem Aghamir²

Affiliations

¹ Sina Hospital, Department of Urology, School of Medicine, Tehran University of Medical Sciences Tehran, IRAN.
² Urology Research Center (URC), Tehran University of Medical Sciences Tehran, IRAN.

PMID: 31763366
PMCID: PMC6872472

Abstract

Botulinum toxins were primary suggested for the neurogenic lower urinary tract dysfunction (LUTD) treatment about thirty years ago. The application of BTX-A in LUTD have just developed and the approval of BTX-A injection confirmed in for patients with both overactive bladders (OAB) and neurogenic detrusor overactivity (NDO). Actually the BTX-A medication in interstitial cystitis/bladder pain syndrome (IC/BPS) is not licensed, but there is under consideration. Despite BTX-A is recommended to treat patients with interstitial cystitis/bladder pain syndrome (ICBPS) under different occasions, its efficacy and safety in the cure of (IC/BPS) is under consideration. One difficulty is related to the toxin delivering systems. It is shown that there is no difference in BTX-A injection to body or trigone but there is a need on further large-scale studies over this subject. Moreover, Hydro distention can boost the therapeutic effect of BTX-A for IC/BPS patients. Additional studies should consider the safety and efficacy of BTX-A injection in the treatment of BTX-A.

Keywords: Interstitial cystitis/bladder pain syndrome (IC/BPS); botulinum toxin-A; delivering systems.